Sieper J, Porter-Brown B, Thompson L, Harari O, Dougados M. Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: Results of randomized, placebo-controlled trials. Ann Rheum Dis 2013; epub ahead of print.
Schoels MM, van der Heijde D, Breedveld FC, et al. Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: Systematic literature review and meta-analysis informing a consensus statement. Ann Rheum Dis 2013;72:583-9.
Dougados M, Gueguen A, Nakache JP, et al. Clinical relevance of C-reactive protein in axial involvement of ankylosing spondylitis. J Rheumatol 1999;26:971-4. (Pubitemid 29195696)
Spoorenberg A, van der Heijde D, de Klerk E, et al. Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol 1999;25:980-4. (Pubitemid 29195698)
Braun J, Bollow M, Neure L, et al. Use of immunohistologic and in situ hydridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995:38:499-505.
Van den Bosch F, Kruithof E, De Vos M, De Keyser F, Mielants H. Crohn's disease associated with spondylarthropathy: Effect of TNF-α blockade with infliximab on articular symptoms. Lancet 2000;356:1821-2.
Davis JC, van der Heijde D, Braun J, et al. for the Enbrel ankylosing spondylitis study group. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trial. Arthritis Rheum 2003;48:3320-6.
Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus. Arthritis Rheum 2004;50:3161-9. (Pubitemid 39371992)
Desai SB, Furst DE. Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol 2006;20:757-90. (Pubitemid 44350122)
Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: Findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000;43:2383-90.
Williams EL, Gadola S, Edwards CJ. Anti-TNF-induced lupus. Rheumatology 2009;48:716-20.
Ramos-Casals M, Brito-Zerón P, Muñoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: Analysis of 233 cases. Medicine (Baltimore) 2007; 86:242-51. (Pubitemid 47067483)
Costa MF, Said NR, Zimmermann B. Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Semin Arthritis Rheum 2008;37:381-7. (Pubitemid 351734520)
Aringer M, Steiner G, Graninger WB, et al. Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus. Arthritis Rheum 2007; 56:274-9. (Pubitemid 46106201)
Aringer M, Smolen JS. TNF inhibition in SLE: Where do we stand? Lupus 2009;18:5-8.
Aringer M, Houssiau F, Gordon C, et al. Adverse events and efficacy of TNF-α blockade with infliximab in patients with systemic lupus erythematosus: Longterm follow-up of 13 patients. Rheumatology 2009;48: 1451-4.
Aringer M, Smolen J. Therapeutic blockade of TNF in patients with SLE-Promizing or crazy? Autoimmun Rev 2012;11:321-5.
Daikh DI, Wofsy O. Cutting hedge. Reversal of murine lupus nephritis with CTLA4-Ig and cyclophosphamide. J Immunol 2001;166:2913-6. (Pubitemid 33117284)
Takiguchi M, Murakami M, Nakagawa I, et al. CTLA4- IgG gene delivery prevents autoantibody production and lupus nephritis in MRL/lpr mice. Life Sci 2000; 66:991-1001. (Pubitemid 30090389)
Furie R, Nicholls K, Cheng TT, et al. Efficacy and safety of abatacept over 12 months in patients with lupus nephritis: Result from a multicenter, randomized, double-blind, placebo-controlled phase II/III [abstract]. Arthritis Rheum 2011:63(Suppl.):S962-3.
Wofsy D, Hillson JL, Diamond B. Abatacept for lupus nephritis. Alternative definitions of complete remission support conflicting conclusions. Arthritis Rheum 2012;64:3660-5.
Bahlis NJ, King AM, Kolonias D, et al. CD28 mediated regulation of multiple myeloma cell proliferation and survival. Blood 2007;109:5002-10. (Pubitemid 46827800)
Lu TY, Ng KP, Cambridge G, et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College Hospital: The first fifty patients. Arthritis Rheum 2009;61:482-7.
Favas C, Isenberg DA. B-cell depletion therapy in SLE - what are the current prospects for its acceptance. Nat Rev Rheumatol 2009;5:711-6.
Terrier B, Amoura Z, Ravaud P, et al. Safety and efficacy of rituximab in systemic lupus erythematosus. Results from 136 patients from the french autoimmunity and rituximab registry. Arthritis Rheum 2010;62: 2458-66.
Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severe active systemic lupus erythematosus. The randomized, doubleblind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010;62:222-33.
Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis. The lupus nephritis assessment with rituximab study. Arthritis Rheum 2012;64:1215-26.
Lightstone L. The landscape after LUNAR: Rituximab's crater-filled path. Arthritis Rheum 2012;64: 962-5.
Isenberg DA. Rituximab - it was the best of times, it was the worst of times. Autoimmun Rev 2012;11: 790-1.
Diaz-Lagares C, Croca S, Sangle S, et al. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: Pooled data from european cohorts. Autoimmun Rev 2012;11:357-64.
Dorner T, Kaufmann J, Wegener WA, et al. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 2006;8:R74.
Petri M, Hobbs K, Gordon C, et al. Clinically meaningful improvements with epratuzumab (anti-CD22 mab targeting B-cells) in patients (pts) with moderate/severe systemic lupus erythematosus (SLE) flares: Results from 2 randomized controlled trials. Arthritis Rheum 2008;57(Suppl.):1087.
Strand V. Meaningful improvements in health-related quality of life (HRQoL) with epratuzumab (anti- CD22 mAb targeting B cells) in patients (pts) with SLE with high disease activity: Results from 2 randomised controlled trials (RCTs). Arthritis Rheum 2008;57 (Suppl.):1086.
Wallace DJ. Epratuzumab (anti-CD22 mAb targeting B cells) provides clinically meaningful reductions in corticosteroids (CS) use with a favourable safety profile in patients with moderate/severe flaring SLE: Results from 2 randomised controlled trials. Arthritis Rheum 2008;57(Suppl.):1088.
Wallace DJ, Kalunian K, Petri M, et al. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: Result from EMBLEM, a phase IIb, randomised, double blind, placebocontrolled, multicentre study. Ann Rheum Dis 2013; epub ahead of print.
Wallace DJ, Gordon C, Strand V, et al. Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: Results from two randomised, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. Rheumatology 2013;52:1313-22.
Moore PA, Belvedere O, Orr A, et al. BLys: Member of the tumor necrosis family and B lymphocyte stimulator. Science 1999;285:260-3. (Pubitemid 29330000)
Petri M, Stohl W, Chatham W, et al. Association of plasma B-lymphocyte stimulator (BLys) levels and disease activity in systemic lupus erythematosus. Arthritis Rheum 2008;58:2453-9.
Baker KP, Edwards BM, Main SH, et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 2003;48:3253- 65. (Pubitemid 37409340)
Navara SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:721-31.
Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63:3918-30.
Manzi S, Sanchez-Guerrero J, Merrill JT, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: Combined results from two phase III trials. Ann Rheum Dis 2012;71:1833-8.
Dooley MA, Houssiau F, Aranow C, et al. Effect of belimumab treatment on renal outcomes: Results from the phase 3 belimumab clinical trials in patients with SLE. Lupus 2013;22:63-72.
